ArticleArchives of toxicology2026
The use of cultured human hepatocytes as a test system to evaluate cell proliferation as a key event in nongenotoxic carcinogenesis.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The objective of this study was to evaluate the applicability of replicative DNA synthesis (RDS) in cultured human hepatocytes as an in vitro model to evaluate the carcinogenicity of nongenotoxic chemicals and species differences. Investigations were performed with 39 cryopreserved human hepatocyte preparations from predominantly Caucasian male and female donors aged 10 months to 80 years and were conducted by two separate laboratories, which employed different culture conditions and methodology for evaluating effects on hepatocyte RDS. For all male and female human hepatocyte preparations of all ages examined, treatment with either epidermal growth factor (EGF) and/or hepatocyte growth factor (HGF) resulted in a stimulation of RDS. In contrast, the treatment of human hepatocytes with the constitutive androstane receptor (CAR) activators phenobarbital and CITCO and the peroxisome proliferator-activated receptor alpha (PPARα) activator WY-14,643 did not result in any increases in RDS. These findings are in agreement with previous studies where, unlike EGF and HGF, nongenotoxic CAR and PPARα activators are mitogenic agents in rodent but not in human hepatocytes. While some donor to donor variability was observed, the qualitative inducibility of RDS by EGF and/or HGF in human hepatocytes was not sex-, age-, or, based on a limited number of samples examined, ethnicity-dependent. These studies demonstrate that cultured cryopreserved human hepatocytes are an established, reproducible and relevant in vitro test system for investigating the nongenotoxic carcinogenic potential of chemicals and species differences, and worth progressing to formal validation according to OECD principles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.